FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Histidine topics
Amino Acid
Amino Acids
Genetically
Antibodies
Immunoglobulin
Polypeptide
Nucleic Acid
Pertuzumab
Trastuzumab
Mesoporous Silica
Hemoglobin
Specificity
Carrier Molecule
Blood Plasma
Recombinant

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Histidine patents



      
           
This page is updated frequently with new Histidine-related patent applications. Subscribe to the Histidine RSS feed to automatically get the update: related Histidine RSS feeds. RSS updates for this page: Histidine RSS RSS


Date/App# patent app List of recent Histidine-related patents
08/21/14
20140235503
 Prediction method of glomerular filtration rate from urine samples after kidney transplantation patent thumbnailPrediction method of glomerular filtration rate from urine samples after kidney transplantation
Disclosed is a prediction method of glomerular filtration rate (gfr) from urine samples after kidney transplantation to provide an information needed for predict renal function after the transplantation, more particularly to a prediction method of glomerular filtration rate (gfr) from urine samples after kidney transplantation, which comprises detecting metabolic profiles of five biomarkers, 5a-androst-3-en-17-one (as), glycocholic acid (gc), sphingosine (sg), tryptophan (tr) and histidine (ht), from urine samples of patients. Glomerular filtration rate (gfr) after kidney transplantation can be predicted more rapidly and precisely to provide an information needed for predict renal function after the transplantation by using five metabolites as biomarkers.
08/21/14
20140234187
 Valuable metal extraction agent and valuable metal extraction method using said extraction agent patent thumbnailValuable metal extraction agent and valuable metal extraction method using said extraction agent
The objective of the present invention is to selectively extract light rare earth metals, and by extension, europium, from an acidic solution containing a plurality of types of rare earth metal. This valuable metal extraction agent is represented by the general formula.
08/14/14
20140227728
 Novel fructosyl peptidyl oxidase patent thumbnailNovel fructosyl peptidyl oxidase
In one form, a fructosyl peptidyl oxidase derived from a budding yeast phaeosphaeria nodorum for assaying a glycated protein in a sample is provided. The fructosyl peptidyl oxidase has higher activity toward fructosyl valine as well as fructosyl valyl histidine, and may be useful in assaying hba1c with higher sensitivity and specificity.
08/07/14
20140220644
 Improved nitrile hydratase patent thumbnailImproved nitrile hydratase
Provided is an improved nitrile hydratase with improved catalytic activity. Also provided are dna for coding the improved nitrile hydratase, a recombinant vector that contains the dna, a transformant that contains the recombinant vector, nitrile hydratase acquired from a culture of the transformant, and a method for producing the nitrile hydratase.
08/07/14
20140220147
 Pharmaceutical composition comprising factor vii encapsulated in micelles patent thumbnailPharmaceutical composition comprising factor vii encapsulated in micelles
The invention relates to a pharmaceutical composition comprising factor vii encapsulated in micelles formed from block copolymer molecules containing (i) a hydrophilic polymer segment consisting of a polyalkylene glycol and (ii) a hydrophobic polymer segment consisting of a polyamino acid, with said polyamino acid comprising exclusively amino acid residues selected from the group consisting of histidine, lysine, aspartic acid and glutamic acid residues, wherein a part of said amino acid residues is substituted with a hydrophobic group.. .
07/24/14
20140206533
 Organic syringomycin methods and compositions patent thumbnailOrganic syringomycin methods and compositions
Methods and materials for producing organic syringomycin, the methods include culturing a culture of pseudomonas syringae and a growth medium including glucose, mannitol, histidine, a magnesium source, an iron source, and a buffer with a ph of from about 6.5 to 7; extracting syringomycin from the culture to yield an extract; and purifying the extract to yield syringomycin.. .
07/24/14
20140205711
 Dipeptides as feed additives patent thumbnailDipeptides as feed additives
The invention relates to feed additives containing dipeptides or salts thereof, in which one amino acid residue of the dipeptide is a dl-methionyl residue and the other amino acid residue of the dipeptide is an amino acid in the l-configuration selected from lysine, threonine, tryptophan, histidine, valine, leucine, isoleucine, phenylalanine, arginine, cysteine and cystine; feed mixtures containing these additives and method of producing the dipeptides.. .
07/17/14
20140199303
 Stable liquid formulation of etanercept patent thumbnailStable liquid formulation of etanercept
The present invention relates to a stable liquid formulation of etanercept (recombinant p75 stnfr:fc fusion protein), and more particularly, to a liquid formulation comprising one or more stabilizers selected from the group consisting of methionine, lysine, histidine, and pharmaceutically acceptable salts thereof in an amount sufficient to reduce by-product formation of etanercept during storage. The liquid formulation according to the present invention effectively reduces production of etanercept by-products and to stably maintain its pharmaceutical efficacies for long-term storage.
07/10/14
20140194359
 Interfering rna delivery system and uses thereof patent thumbnailInterfering rna delivery system and uses thereof
The invention provides a delivery system comprising a cell penetrating peptide, 10 histidines, and an interfering rna molecule. The system can be used for delivering interfering rna molecules into a cell in vivo or in vitro.
07/03/14
20140186415
 Polymer composition and polymer material patent thumbnailPolymer composition and polymer material
A polymer composition including a polymer having a hydroxyl group and a histidine or a histidine derivative grafted to the polymer having a hydroxyl group. A polymer material is also provided, including a polymer composition which includes a polymer having a hydroxyl group, and a histidine or a histidine derivative grafted to the polymer having a hydroxyl group..
06/26/14
20140179898
Mutated protein of protein a having reduced affinity in acidic region and antibody-capturing agent
A modified protein of an extracellular domain of protein a, which has the reduced ability to bind to immunoglobulin in an acidic region, compared with the wild-type extracellular domain of protein a, without impairing a selective antibody-binding activity in a neutral region. On the basis of three-dimensional structure coordinate data on a complex of the extracellular domain of protein a bound with the fc region of immunoglobulin g, the modified protein is obtained by the substitution of amino acid residues that are located within the range of 10 angstroms from the fc region and have a 20% or more ratio of exposed surface area, by histidine residues.
06/26/14
20140178460
Lyase enzymes, nucleic acids encoding them and methods for making and using them
This invention provides polypeptides having lyase activity, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides having ammonia lyase activity, e.g., phenylalanine ammonia lyase, tyrosine ammonia lyase and/or histidine ammonia lyase activity, including thermostable and thermotolerant activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides.
06/12/14
20140161723
In vivo methods of monitoring biodistribution
Functional-lipid constructs of the structure f-s-l are disclosed, wherein f comprises a tyrosine or histidine residue, s is a spacer covalently linking f to l and l is a lipid. The functional residue may be iodinated and used to radiolabel a biological entity with 1251 and the iodinated constructs are used in a non-invasive method of monitoring the distribution of a biological entity in vivo..
06/05/14
20140155449
New use of l-histidine and derivatives thereof
The present invention discloses the use of l-histidine to reduce gadolinium accumulation into target organs, preventing its toxic effects, after administration of gadolinium based contrast agents. The invention thus, also disclose the use of l-histidine to prevent the nsf syndrome in patients with renal functionality impairment.
06/05/14
20140154752
Glycoside hydrolases having multiple hydrolase activities
Glycoside hydrolases having at least two different hydrolytic activities are provided. In one embodiment, an isolated recombinant hydrolase having at least two activities selected from a group including asparagine derivatives, glutamine derivatives, and histidine derivatives is provided.
05/29/14
20140148532
Adhesive composition
A adhesive composition that includes at least the main components of a hydrolyzable tannin and at least one cationic polymer selected from the group including (poly-)lysine, (poly-)-dl-ornithine, ε-poly-ornithine, (poly-)arginine, (poly-)glutamine, (poly-)asparagine, (poly-)histidine, (poly-)proline, putrescine, spermidine, spermine, cadaverine, agmatine, citrulline and mixtures thereof.. .
05/15/14
20140134232
Encapsulation of plasmid dna (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
A method is disclosed for encapsulating plasmids, oligonucleotides or negatively-charged drugs into liposomes having a different lipid composition between their inner and outer membrane bilayers and able to reach primary tumors and their metastases after intravenous injection to animals and humans. The formulation method includes complex formation between dna with cationic lipid molecules and fusogenic/nls peptide conjugates composed of a hydrophobic chain of about 10-20 amino acids and also containing four or more histidine residues or nls at their one end.
05/08/14
20140127693
Fertilization prediction and promotion
The outcome of an in vitro fertilization (ivf) of a woman in terms of chances of successful pregnancy or the fertility status of a woman is predicted based on nucleotide analysis of the histidine-rich glycoprotein (hrg) gene or protein analysis of hrg. The proline isoform of hrg or an amino acid fragment thereof can further be used to increases the success of pregnancy of a woman..
05/08/14
20140127144
Flavour modifying compounds
Wherein r1 is h, or a substituted, unsubstituted, branched or unbranched c1-c5 alkyl group and, nhr2 is a residue of an amino acid, is selected from alanine (ala), cysteine (cys), aspartic acid (asp), phenylalanine (phe), glutamic acid (glu), histidine (his), isoleucine (ile), lysine (lys), leucine (leu), methionine (met), asparagines (asn), glutamine (gln), arginine (arg), serine (ser), theronine (thr), valine (val), tryptophan (trp), tyrosine(tyr) and glycine (gly), with the proviso that the compound is not n-acetyl glycine. Also disclosed are flavour compositions and consumable products containing such compounds..
04/17/14
20140106431
High fidelity thermostable ligase and uses thereof
The present invention is directed to a mutant thermostable ligase having substantially higher fidelity than either t4 ligase or thermus thermophilus ligase. The ligase of the present invention is a mutant of a wild-type thermostable ligase having a histidine adjacent a kxdg motif, where the mutant thermostable ligase has a mutation in its amino sequence where the histidine adjacent the kxdg motif in the wild-type thermostable ligase is replaced with an arginine, and wherein x is any amino acid.
04/10/14
20140099667
Bacteriorhodopsin fusion membrane protein expression system
An expression vector is disclosed, which comprises: a) a polynucleotide sequence encoding a bacteriorhodopsin or a mutant bacteriorhodopsin; b) a multiple cloning site; c) a t7 promoter, d) a polyhistidine tag; e) a first protease cleavage site; f) optionally a second protease cleavage site; and g) optionally a linker; wherein the mutant bacteriorhodopsin comprises the residue corresponding to asn94 of seq id no: 1. Also disclosed is a fusion membrane protein expression system, which comprises: a) a polynucleotide sequence encoding a mutant haloarcula marismortui bacteriorhodopsin/d94n (hmbri/d94n) or a haloquadratum walsbyi bacteriorhodopsin (hwbr); b) a target membrane protein; and c) a t7 promoter, operably linked to the mutant hmbri/d94n or hwbr and the target membrane protein.
04/03/14
20140093472
L-histidine in ophthalmic solutions
The invention relates to an aqueous ophthalmic solution comprising 0.00001 to about 10.0 percent by weight l-histidine, 0.0001 to 3.0 percent by weight hydrogen peroxide, and optionally 0.1 to 500 parts per million of a preservative that provides superior preservative efficacy especially as against fungal microbes. These solutions may be employed in various ways including cleaning contact lenses, rinsing lenses while in the eye, storing lenses and in delivering active pharmaceutical agents to the eye..
03/27/14
20140088166
Process of making and using pharmaceutical formulations of antineoplastic agents
In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at least one antineoplastic agent in at least one aqueous diluent, wherein said dissolution enhancing agent is urea, l-histidine, l-threonine, l-asparagine, l-serine, l-glutamine or mixtures thereof; a lyophilized powder comprising said pharmaceutical formulation, and articles of manufacture thereof.. .
03/20/14
20140082760
Non-human animals expressing ph-sensitive immunoglobulin sequences
Genetically modified non-human animals are provided that express an immunoglobulin variable domain that comprises at least one histidine, wherein the at least one histidine is encoded by a substitution of a non-histidine codon in the germline of the animal with a hisidine codon, or the insertion of a histidine codon in a germline immunoglobulin nucleic acid sequence. Immunoglobulin genes comprising histidines in one or more cdrs, in an n-terminal region, and or in a loop 4 region are also provided.
03/13/14
20140072622
Vaccine against streptococcus pneumoniae
The present invention relates to improved immunogenic compositions and vaccines, methods for making them and their use in medicine. In particular the invention relates to immunogenic compositions of unconjugated streptococcus pneumoniae proteins selected from: pneumolysin and member(s) of the polyhistidine triad family (e.g.
02/27/14
20140058069
Particles and other substrates useful in protein purification and other applications
The present invention generally relates to particles, including microgel particles, for purifying proteins and other species. In one aspect, the particles comprise a metal-chelating moiety, which may be distributed substantially evenly throughout the particle in certain embodiments.
02/27/14
20140057328
Yeast cell for the production of terpenes and uses thereof
The present invention relates to a yeast cell, wherein said cell comprises a functional gene coding for soluble hydroxymethylglutaryl-coenzyme-a (hmg-coa) reductase; one or more gene(s) coding for steryl acyltransferase(s) in said cell are defective or deleted; and said cell is prototrophic for at least histidine, leucine or uracil. Moreover, the present invention relates to the use of said cell for the production of one or more terpene(s).
02/20/14
20140051628
Composition for long-acting peptide analogs
The invention describes compositions of peptide analogs that are active in blood or cleavable in blood to release an active peptide. The peptide analogs have a general formula: a-(cm)x-peptide (seq id no: 76), wherein a is hydrophobic moiety or a metal binding moiety, e.g., a chemical group or moiety containing 1) an alkyl group having 6 to 36 carbon units, 2) a nitrilotriacetic acid group, 3) an imidodiacetic acid group, or 4) a moiety of formula (zyhisw)p (seq id no: 50), wherein z is any amino acid residue other than histidine, his is histidine, y is an integer from 0-6; w is an integer from 1-6; and p is an integer from 1-6; wherein if a has alkyl group with 6 to 36 carbon units x is greater than 0; and cm is a cleavable moiety consisting of glycine or alanine or lysine or arginine or n-arginine or n-lysine, wherein x is an integer between 0-6 and n may be any amino acid or none.
02/13/14
20140046040
Method for selective derivatization of oligohistidine sequence of recombinant proteins
Methods and compositions for the selective derivatization of a oligohistidine-tagged recombinant protein. A modifying compound comprised of an imidazole reactive group, a linker, and a ligating group is contacted with the recombinant protein, and a cooperative bond forms between the ligating group and the oligohistidine tag in the presence of a metal cation, and a covalent bond forms between the imidazole reactive group and an imidazole ring of the oligohistidine tag followed by the concomitant separation of the imidazole reactive group from the linker.
02/13/14
20140045244
Reverse transcriptase having improved thermostability
The present invention relates to a reverse transcriptase having improved thermostability, more precisely a mutant reverse transcriptase with improved thermostability by substitution of one or more amino acids selected from the group consisting of the 63rd glutamine (q63), the 264th lysine (k264), the 295th lysine (k295), the 306th threonine (t306), the 346th glutamic acid (e346), the 408th proline (p408), the 438th histidine (h438), and the 454th asparagin (n454) of the amino acid sequence of m-mlv originated reverse transcriptase represented by seq. Id.
02/13/14
20140044778
Nanoparticles containing ph-responsive peptide
The present invention provides a nanoparticle and cell induction agent, capable of releasing a target substance in a weakly acidic ph environment. Specifically, the present invention provides a nanoparticle comprising a peptide and a particle-forming component, the particle-forming component forming a liposome or a micelle, the peptide having a sequence with 2 to 8 units starting with his (histidine) and ending with an acidic amino acid, wherein each of the units may be identical or different..
02/13/14
20140044730
Anti-pcsk9 antibodies with ph-dependent binding characteristics
The present invention provides antibodies and antigen-binding fragments thereof that specifically bind proprotein convertase subtilisin/kexin-9 (pcsk9) with greater affinity at neutral ph than at acidic ph. The antibodies of the invention may possess one or more amino acid changes as compared to antibodies that do not exhibit ph-dependent binding properties.
02/06/14
20140039158
Polymeric conjugates and methods of preparing the same
Methods of preparing polymer target conjugates which are substantially free of polymer attachment on the n-terminal of the targets are provided. Also provided are compositions comprising a plurality of polymer-polypeptide conjugates, said polymer-polypeptide conjugate comprising a polypeptide covalently attached to at least one polymer through an epsilon amino group of a lysine or a histidine found on the polypeptide and said conjugates containing less than 5% of the polymer-polypeptide conjugates having a polymer attached to the n-terminal of the polypeptide; and polymer target conjugates comprising a target moiety selected from the group consisting of polypeptides, proteins and the like having at least one polymer attached thereto at a site which is not the n-terminal of the target..
02/06/14
20140038856
Site-specific labeling of affinity tags in fusion proteins
The present invention provides methods and fluorescent compounds that facilitate detecting and labeling of a fusion protein by being capable of selectively binding to an affinity tag. The fluorescent compounds have the general formula a(b)n, wherein a is a fluorophore, b is a binding domain that is a charged chemical moiety, a protein or fragment thereof and n is an integer from 1-6 with the proviso that the protein or fragment thereof not be an antibody or generated from an antibody.
02/06/14
20140037574
Pharmaceutical composition
The invention provides a pharmaceutical composition for oral administration of a pharmaceutically active agent to a subject, including the pharmaceutically active agent and an inhibitor of cyp3a4. Administration of the inhibitor and the pharmaceutically active agent reduces pre-systemic degradation of the pharmaceutically active agent by cyp3a4.
01/30/14
20140031522
Novel alkali-resistant variants of protein a and their use in affinity chromatography
The present invention relates to immunoglobulin (ig)-binding proteins with alkali-resistance properties. In one embodiment, the present invention provides for a variant of an ig-binding protein, the variant comprising the ig-binding protein having at least one asparagine residue substituted with a histidine, a serine, an aspartic acid or a threonine residue.
01/09/14
20140013456
Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of ph dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses human immunoglobulin light chain variable domains derived from a limited repertoire of human immunoglobulin light chain variable gene segments that comprise histidine modifications in their germline sequence.
12/26/13
20130345284
Sirna compositions and methods for treatment of hpv and other infections
The invention provides sirna compositions that (1) interfere with viral replication of human papillomavirus (hpv), herpes simplex virus (hsv), and human immunodeficiency virus (hiv) in mucosal tissues, such as genital tissues, and (2) treat fungal infections. The compositions include sirna molecules that target hpv, complexed with a dendrimer that treats and prevents genital herpes (hsv) and hiv.
12/19/13
20130338339
Affinity chromatography matrix
The present invention relates to a method of separating one or more immunoglobulin containing proteins from a liquid. The method includes first contacting the liquid with a separation matrix comprising ligands immobilised to a support; allowing the immunoglobulin containing proteins to adsorb to the matrix by interaction with the ligands; followed by an optional step of washing the matrix containing the immunoglobulin containing proteins adsorbed thereon; and recovering said immunoglobulin containing proteins by contacting the matrix with an eluent which releases the proteins.
11/14/13
20130303377
Use of single amino acids at low concentrations for influencing the life processes of crops
This invention relates to the use of a composition in low doses containing single l-amino acids, including their precursors and biologically still active metabolites, to influence the life processes of plants, such as their growth, whereby the total amount of single l-amino acids when applying the composition is at least 0.5 g/ha and at most 250 g/ha, and wherein the l-amino acids are selected from the group of glutamine, asparagine, aspartic acid, histidine, lysine, and combinations thereof with each other and/or with arginine and/or with glutamic acid.. .
10/17/13
20130273126
Tooth bleaching catalytic and application thereof
A method for forming a tooth bleaching catalytic is provided, wherein the method comprises steps as follows: firstly a plurality of histidine-functionalized mesoporous silica nano-particles (msns) is provided. Subsequently, the histidine-functionalized msns are condensating with a plurality of metal ions..
10/10/13
20130267007
Amadoriase having altered substrate specificity
This invention provides an amadoriase having high substrate specificity to fructosyl valyl histidine. Such amadoriase comprises substitution of one or more amino acid residues at positions corresponding to amino acids selected from the group consisting of position 98, position 259, position 154, position 125, position 261, position 263, position 106, position 103, position 355, position 96, position 66, position 67, position 70, position 100, position 110, position 113, position 114, and position 156 in the amadoriase derived from the genus coniochaeta.
10/03/13
20130261336
Methods and compositions for increasing the anaerobic working capacity in tissues
Provided are compositions comprising beta-alanylhistidine peptides and/or beta-alanines, and methods for administering these peptides and amino acids. In one aspect, the compositions and methods cause an increase in the blood plasma concentrations of beta-alanine and/or creatine..
10/03/13
20130260398
Phosphohistidine analogs
The present invention relates to the phosphohistidine analogs of the present invention which of the formula (i) and the hapten containing the residue of same. It also relates to the hapten conjugated to a carrier molecule and the isolated antibodies raised against the immunogens, said antibodies recognizing polypeptide containing a phosphorylated histidine or the phosphotriazole residue but it does not recognize an amino acid or polypeptide that is not phosphorylated or a polypeptide which is phosphorylated on amino acids other than histidine but not on histidine..
09/19/13
20130247236
Non-human animals expressing ph-sensitive immunoglobulin sequences
Genetically modified non-human animals are provided that express an immunoglobulin variable domain that comprises at least one histidine, wherein the at least one histidine is encoded by a substitution of a non-histidine codon in the germline of the animal with a hisidine codon, or the insertion of a histidine codon in a germline immunoglobulin nucleic acid sequence. Immunoglobulin genes comprising histidines in one or more cdrs, in an n-terminal region, and or in a loop 4 region are also provided.
09/19/13
20130247235
Mice that produce antigen-binding proteins with ph-dependent binding characteristics
Genetically modified non-human animals are provided that comprise an immunoglobulin heavy chain locus comprising an unrearranged human heavy chain variable region nucleotide sequence comprising an addition of at least one histidine codon or a substitution of at least one endogenous non-histidine codon with a histidine codon. Compositions and methods for making the genetically modified non-human animals as described herein are provided.
09/19/13
20130247234
Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of ph dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses a single light chain variable domain derived from a single rearranged light chain variable region gene in the germline of the non-human animal, wherein the single rearranged light chain variable region gene comprises a substitution of at least one non-histidine encoding codon with a histidine encoding codon.
09/05/13
20130230562
Fusion protein comprising small heat shock protein, cage protein formed thereby, and novel use thereof
The present invention relates to a fusion protein comprising small heat shock protein, a cage protein formed thereby, and novel use thereof, more particularly, a fusion protein comprising a small heat shock protein, a recognition site of a protease, and a histidine polymer, wherein the recognition site and the histidine polymer are sequentially linked to a carboxyl terminal of the small heat shock protein, a cage protein formed thereby, and novel use thereof. The fusion protein of the present invention, and a cage protein formed by the self-assembly properties of the fusion protein are not cytotoxic, and emits a fluorescence signal of about 20 to about 50 times higher comparing to a single peptide for the conventional molecular imaging, per unit protein.
08/22/13
20130216532
Subcutaneous anti-her2 antibody formulations and uses thereof
The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-her2 antibody, such as e.g. Trastuzumab (herceptin™), pertuzumab or t-dm1, or a mixture of such antibody molecules for subcutaneous injection.
08/15/13
20130210023
Nucleic acid aptamers against plasmodium lactate dehydrogenase and histidine-rich protein ii and uses thereof for malaria diagnosis
The present invention provides nucleic acid aptamers that bind to plasmodium proteins lactate dehydrogenase and histidine-rich protein ii, and uses thereof for the diagnosis of malaria. Aptamers against histidine-rich protein ii may be used to detect the presence of plasmodium species in general, whereas aptamers against lactate dehydrogenase can be used to specifically detect plasmodium falciparum..
08/08/13
20130203185
Method for immobilizing a protein on self-assembled monolayer
One molecule of the amino acid selected from the five kinds of amino acids consisting of cysteine, lysine, histidine, phenylalanine, and glycine is interposed between a self-assembled monolayer and a molecule of a protein. A method for immobilizing an protein on a self-assembled monolayer includes the following steps (a) and (b) in this order: a step (a) of preparing a substrate including one molecule of an amino acid and the self-assembled monolayer and a step (b) of supplying the protein to the substrate to form a peptide bond represented by a predetermined chemical formula as a result of reaction between the carboxyl group of the one molecular of the amino acid and the amino group of the protein..
08/01/13
20130195916
System and method for identifying complex patterns of amino acids
A method and system are disclosed for identifying and/or locating complex patterns in an amino acid sequence stored in a computer file or database. According to an aspect of the present invention, techniques are provided to facilitate queries of protein databases.
07/25/13
20130189249
Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
Embodiments of the invention include methods and compositions useful in a vaccination strategy capable of neutralizing hla to provide immunoprotection against s. Aureus pneumonia.
07/18/13
20130183350
Immunogenic compositions
This disclosure relates to immunogenic compositions comprising an isolated immunogenic s. Pneumoniae pcpa polypeptide and at least one additional antigen (such as for example, an isolated immunogenic s.
07/18/13
20130181171
Metamaterial optical elements self-assembled on protein scaffolds
Protein scaffolds from tobacco mosaic virus coat protein modified to incorporate polyhistidine can bind to a metal or a dye while having improved self-assembly characteristics. The scaffold can take the form of tubes or disks, and can further be formed into dual plasmonic ring resonators.
07/11/13
20130178421
Interfering rna delivery system and uses thereof
The invention provides a delivery system comprising a cell penetrating peptide, 10 histidines, and an interfering rna molecule. The system can be used for delivering interfering rna molecules into a cell in vivo or in vitro.
07/11/13
20130177940
C-terminal modification of polypeptides
The invention relates to a mutated trypsin comprising an amino acid substitution both at position k60 and d189, and at least one more amino acid substitution by histidine at position n143 or position e151. Such trypsin mutant has a preferred cleavage site comprising the amino acids xaa1-xaa2-his, wherein xaa1 is l, y or f and xaa2 is r or k.
06/20/13
20130157337
Template-directed assembly of receptor signaling complexes
Transmembrane receptors in the signaling pathways of bacterial chemotaxis systems influence cell motility by forming noncovalent complexes with the cytoplasmic signaling proteins to regulate their activity. The requirements for receptor-mediated activation of chea, the principal kinase of the escherichia coli chemotaxis signaling pathway, can be demonstrated using self-assembled clusters of a receptor fragment (cf) derived from the cytoplasmic domain of the aspartate receptor, tar.
06/20/13
20130157327
Mutant polyhydroxyalkanoic acid synthase gene and method for producing aliphatic polyester using the same
A substitution mutation that improves polymerization activity of a polyhydroxyalkanoic acid synthase is identified. At least 1 amino acid residue selected from the group consisting of a histidine residue at position 17, a proline residue at position 71, a valine residue at position 131, a methionine residue at position 205, a leucine residue at position 230, and a proline residue at position 239 of a polyhydroxyalkanoic acid synthase derived from alcanivorax borkumensis is subjected to substitution mutation with another amino acid..
06/13/13
20130149291
Production and use of bacterial histamine
A method is provided of selecting specific probiotic lactic acid bacteria producing histamine and the use of such strains for beneficial effects for mammals. The method includes selecting a lactic acid bacterial strain for use in the local production of histamine in a mammal, and further comprises screening bacteria for the presence of an.
05/23/13
20130131104
Histidine rich protein-2 diagnostic test for cerebral malaria
The present inventions relate to accurately identifying a subset of patients within a larger group with malarial parasitemia. In particular, the present inventions provide compositions and methods comprising a malarial protein, histidine rich pro-tein-2 (hrp-2) for determining the general severity of a malarial infection in patients.
05/02/13
20130109626
Novel peptide and use thereof
The present invention provides a peptide represented by formula (i) of x1-leu-x2-leu-x3 wherein x1 represents glu or asp, x2 represents his, lys or arg, x3 represents asp or glu, with glu, asp, leu, his, lys and arg being respectively glutamic acid, aspartic acid, leucine, histidine, lysine and arginine; or a pharmaceutically acceptable salt thereof; a composition for the treatment or prevention of at least one selected from cartilage damage and arthritis, containing the same peptide or a pharmaceutically acceptable salt thereof as an active ingredient; and a composition containing the same peptide or a pharmaceutically acceptable salt thereof and tgfβ1. The above-mentioned peptide or a pharmaceutically acceptable salt thereof is effective for the treatment and/or prevention of cartilage damage and/or arthritis and is capable of exhibiting effects of the regeneration of cartilage tissue, the inhibition of the expression of cartilage tissue matrix degrading enzyme and/or the inhibition of cartilage tissue ossification..
05/02/13
20130108731
High protein supplement
The present disclosure relates to high protein dietary supplements for treating various symptoms and diseases associated with protein deficiency including weight gain, obesity, catabolic diseases, fibromyalgia, anxiety reactions, posttraumatic stress and chronic fatigue syndrome. Embodiments of dietary supplements comprise combinations of proteins, essential and semi-essential amino acids including l-lysine, l-arginine, and/or l-histidine..
04/25/13
20130102561
Stabalized glycosaminoglycan preparations and related methods
Compositions comprising a glycosaminoglycan (e.g., a hyaluronan, hyaluronic acid, hyaluronate, sodium hyaluronate, dermatan sulfate, karatan sulfate, chondroitin 6-sulfate, heparin, etc.) in combination with at least one component selected from; i) polyglycols (e.g., polyethylene glycol), ii) long chain hydroxy polyanionic polysaccharides (e.g., dextran, sodium alginate, alginic acid, propylene glycol alginate, carboxymethyl cellulose and carboxyethyl cellulose, hydroxyl ethyl starch, hydroxyl propyl methyl cellulose, hydroxy propyl ethyl cellulose, hydroxy propyl cellulose, methyl cellulose, polylysine, polyhistidine, polyhydroxy proline, poly ornithine, polyvinyl pyrolidone, polyvinyl alcohol, chitosan, etc.) and iii) long chain nitrogen containing polymers (e.g., polylysine, polyvinylpyrrolidone, and polyvinyl alcohol). The invention also includes methods for using such compositions (e.g., as substance delivery materials, tissue fillers or bulking agents, as moistening or hydrating agents, etc.).
04/25/13
20130101681
Use of chromium histidinate for treatment of cardiometabolic disorders
Provided herein are methods for treating, preventing, and improving conditions associated with cardiometabolic syndrome, by identifying a subject in need of treatment, prevention, or improvement of a condition associated with cardiometabolic syndrome, and providing a therapeutically effective amount of a composition comprising chromium and histidine, chromium histidinate complexes, or combinations thereof, to the individual.. .
04/18/13
20130091932
Process and method for broad spectrum amino acid challenged urinary organic acids
Discloses is a process for detecting and evaluating metabolic disturbances and specific nutrient insufficiencies within an individual. The bio-chemical pathways of the individual are challenged by consuming an oral amino acid supplement prior to urine sample collection.
04/04/13
20130085101
Long-acting insulin analogue preparations in soluble and crystalline forms
A pharmaceutical formulation comprises an insulin analogue or a physiologically acceptable salt thereof, wherein the insulin analogue or a physiologically acceptable salt thereof contains an insulin a-chain sequence that contains paired histidine substitutions at a4 and a8, and optionally a substitution at a21. The formulation further contains a pharmaceutically acceptable buffer containing at least about 4 zinc ions per 6 insulin analogue molecules.
03/21/13
20130071384
Antibody formulations
The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain ii of her2 (for example, pertuzumab), and a formulation comprising an antibody that binds to dr5 (for example, apomab).. .
03/07/13
20130059336
Hydrophobic interaction chromatography method
Herein is reported a method for purifying a polypeptide comprising a histidine-tag comprising the steps of i) applying a solution comprising the polypeptide with a histidine-tag to a hydrophobic interaction chromatography material, and ii) recovering the polypeptide comprising a histidine-tag with a solution comprising imidazole or an imidazole-derivative and thereby purifying the polypeptide comprising a histidine-tag, wherein the solution comprising the polypeptide applied to the hydrophobic interaction chromatography material is free of imidazole or an imidazole-derivative and the polypeptide adsorbed to the hydrophobic interaction chromatography material is recovered with a solution comprising imidazole or an imidazole-derivative.. .
03/07/13
20130059096
Methods and coatings for treating biofilms
A method of treating, reducing, or inhibiting biofilm formation by bacteria, the method comprising: contacting an article with a composition comprising an effective amount of a d-amino acid, said composition being essentially free of the corresponding l-amino acid, thereby treating, reducing or inhibiting formation of the biofilm, wherein the d-amino acid is selected from the group consisting of d-alanine, d-cysteine, d-aspartic acid, d-glutamic acid, d-histidine, d-isoleucine, d-lysine, d-leucine, d-asparagine, d-proline, d-glutamine, d-arginine, d-serine, d-threonine, d-valine, d-tryptophan, d-tyrosine, and a combination thereof.. .


Popular terms: [SEARCH]

Histidine topics: Amino Acid, Amino Acids, Genetically, Antibodies, Immunoglobulin, Polypeptide, Nucleic Acid, Pertuzumab, Trastuzumab, Mesoporous Silica, Hemoglobin, Specificity, Carrier Molecule, Blood Plasma, Recombinant

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Histidine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Histidine with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.5034

3194

2 - 1 - 71